Telix Pharmaceuticals Ltd（ASX: TLX）宣布达成2025财年业绩指引，实现营收8.04亿美元（约合12亿澳元）。公司同时推出新型放射性药物Gozellix，标志着其肿瘤靶向治疗产品线的重大拓展。这一突破性进展不仅巩固了Telix在核医学领域的领先地位，更为全球癌症患者提供了更精准的治疗选择。
随着Gozellix的正式商业化，Telix将同步启动全球市场推广计划。该产品已获得美国FDA突破性疗法认定，其临床数据显示对晚期前列腺癌患者具有显著疗效。公司预计新产品将推动2026财年营收实现阶梯式增长，并进一步优化利润率结构。
Telix首席执行官表示，此次双里程碑的达成得益于公司持续的技术创新与全球化战略布局。未来将通过深化与医疗机构的合作，加速前沿放射配体疗法在临床中的应用转化。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.